ConcertAI has acquired CancerLinQ, previously a subsidiary of the American Society of Clinical Oncology (ASCO), to enhance the healthcare learning and research network in oncology.
Alongside the acquisition, ASCO will maintain a multi-year cooperation agreement with CancerLinQ.
Originating from ASCO’s 2013 launch, the new partnership aims to bolster and broaden CancerLinQ’s use of real-world data, analytics, AI, and other technologies, enhancing cancer care and expediting clinical research.
Distinguished as one of the largest entities in oncology real-world data and quality of care technology services globally, CancerLinQ amalgamates clinical data from the majority of major electronic medical record (EMR) systems.
Boasting a network comprising over 100 cancer centres and oncology practices, integration with 10 EMR systems, and a wealth of data from nearly seven million patient records, CancerLinQ empowers oncology care teams and researchers with technological and data-driven innovations to enhance care and accelerate cancer research.
CancerLinQ remains steadfast in its commitment to quality and the advancement of precision medicine principles, striving to broaden the application of real-world data for diverse research purposes.
Additionally, it supports a novel clinical trials initiative stemming from CancerLinQ’s TriaLinQ concepts. Close collaboration with ASCO will persist as CancerLinQ focuses on prioritising the needs of oncology practices and facilitating the expansion of the practice network.
ASCO CEO Clifford Hudis said: “We believe this agreement will provide the resources to fulfil and amplify CancerLinQ’s impact, while allowing ASCO to harness the CancerLinQ platform for quality improvement initiatives and CancerLinQ Discovery data for research to support our mission.
“We expect CancerLinQ to be an important avenue for practices to achieve certification under ASCO’s recently launched ASCO Certified program.”
ConcertAI CEO Jeff Elton said: “CancerLinQ may be one of the most important oncology networks in existence. We are pleased and privileged to be able to advance the original quality improvement goals and follow-on research interests of CancerLinQ in collaboration with ASCO, with urgency and alacrity.
“We are committing more than $250m to the quality solutions, data solutions, and novel clinical trial solutions over the coming few years to achieve the highest quality care, accelerate needed new biomedical innovations, and assure the best possible outcomes for patients.”
